NCT02437409

Brief Summary

ARTESp is a prospective multicenter study in which the pREset thrombectomy system (phenox GmbH\* Germany) will be examined. The effectiveness, safety and the long-term success when using the pREset to treat acute occlusions of cerebral vessels will be analyzed. \*German: "Gesellschaft mit beschränkter Haftung", limited liability company

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
115

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2013

Typical duration for all trials

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2013

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2015

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 28, 2015

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 7, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
3 months until next milestone

Results Posted

Study results publicly available

November 6, 2015

Completed
Last Updated

August 23, 2017

Status Verified

July 1, 2017

Enrollment Period

2.1 years

First QC Date

April 28, 2015

Results QC Date

September 3, 2015

Last Update Submit

July 19, 2017

Conditions

Keywords

Ischemic, Acute

Outcome Measures

Primary Outcomes (1)

  • Neurological Condition of the Patient

    modified Rankin Scale (mRS) Neurological Condition is measured by the "Modified Rankin Scale (mRS)". This scale ranges from 0 - 6: 0 = No symptoms at all; 1. = able to carry out all usual duties and activities; 2. = unable to carry out all previous activities, but able to look after own affairs without assistance; 3. = requiring some help, but able to walk without assistance; 4. = unable to walk without assistance and unable to attend to own bodily needs without assistance; 5. = bedridden, incontinent and requiring constant nursing care and attention; 6. = dead

    90 days after treatment

Secondary Outcomes (5)

  • Neurological Condition of the Patient

    24 to 72 hr after treatment

  • Intracranial Hemorrhage (ICH)

    24 hr after treatment

  • Time From Groin Puncture to Recanalization

    during intervention, up to 3 hr

  • Recanalization of the Target Vessel

    at the end of intervention, up to 3 hr

  • No. of Passages Needed to Reach the Final TICI Score With pREset

    during intervention, up to 3 hr

Interventions

Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

100 patients harboring an acute ischemic stroke in at least one of the major intracranial arteries

You may qualify if:

  • Patient age ≥ 18 and ≤ 85 years.
  • Patients with acute-onset stroke in the 0-6 hour time window for cerebral onset of symptoms and in angiography with a TICI reperfusion (Thrombolysis in Cerebral Infarction) value of 0 or 1 of at least one major cerebral artery (carotid artery, A. media , anterior cerebral artery, basilar artery, vertebral artery, posterior cerebral artery).
  • NIHSS (National Institutes of Health Stroke Scale) ≥ 8
  • Signed Informed Consent by patient / legal representative to participate in the study.

You may not qualify if:

  • Pregnancy
  • Demarcated infarcted area in the initial Cranial CT or intracranial haemorrhage,
  • Rapid improvement of neurological symptoms
  • NIHSS \> 30
  • Anticoagulation with warfarin with INR (international normalized ratio) \> 3.0,
  • Platelets \<30,000,
  • Glucose \<50mg/dl,
  • Life expectancy \<90 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Katharinenhospital

Stuttgart, Baden-Wurttemberg, 70174, Germany

Location

Klinikum rechts der Isar

München, Bavaria, 81675, Germany

Location

Universitätsklinikum Münster

Münster, North Rhine-Westphalia, 48149, Germany

Location

Universitätsklinikum des Saarlandes

Homburg, Saarland, 66424, Germany

Location

Related Publications (1)

  • Prothmann S, Schwaiger BJ, Gersing AS, Reith W, Niederstadt T, Felber A, Kurre W. Acute Recanalization of Thrombo-Embolic Ischemic Stroke with pREset (ARTESp): the impact of occlusion time on clinical outcome of directly admitted and transferred patients. J Neurointerv Surg. 2017 Sep;9(9):817-822. doi: 10.1136/neurintsurg-2016-012556. Epub 2016 Aug 16.

Related Links

MeSH Terms

Conditions

StrokeIschemia

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Clinical Affairs
Organization
phenox GmbH

Study Officials

  • Wolfgang Reith, Prof.

    Universitätsklinikum des Saarlands

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 28, 2015

First Posted

May 7, 2015

Study Start

February 1, 2013

Primary Completion

March 1, 2015

Study Completion

August 1, 2015

Last Updated

August 23, 2017

Results First Posted

November 6, 2015

Record last verified: 2017-07

Locations